---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-001139"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:01:56.065376+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharmaceuticals licenses LB54640 from LG Chem for $60M upfront plus $40M deferred

## Summary
- License deal: $40M cash + $20M stock upfront; additional $40M cash due 18 months after effective date.
- Up to $205M in regulatory and sales milestones; low-to-mid single-digit royalties on MC4R portfolio starting 2029.
- Rhythm assumes sponsorship of two Phase 2 studies: SIGNAL (hypothalamic obesity, ~28 patients) and ROUTE (POMC/LEPR deficiency, 5 patients).
- Cash guidance updated: existing cash sufficient into H2 2025, including $80M fixed payments to LG Chem.

## SEC filing metadata
- accession: 0001104659-24-001139
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/tm2332524d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-001139
- JSON: https://secwatch.observer/filing/0001104659-24-001139.json
- Plain text: https://secwatch.observer/filing/0001104659-24-001139.txt

## Key facts
- Material Agreements
  RHYTHM PHARMACEUTICALS, INC. entered into Share Issuance Agreement with LG Chem, Ltd. (effective 2024-01-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: LG Chem, Ltd.
  - Effective: 2024-01-04
  source text: The Share Issuance Agreement contains customary representations and warranties by the Company and LGC, and the issuance of the Shares is subject to certain customary closing conditions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm
- Material Agreements
  RHYTHM PHARMACEUTICALS, INC. entered into License Agreement with LG Chem, Ltd. valued at $40 million in cash and issue shares of its common stock, par value of $0.001, with an aggregate val (effective 2024-01-04).
  - Action: entry
  - Agreement: license
  - Counterparty: LG Chem, Ltd.
  - Value: $40 million in cash and issue shares of its common stock, par value of $0.001, with an aggregate val
  - Effective: 2024-01-04
  source text: Under the terms of the License Agreement, the Company will obtain worldwide rights to exploit LGC’s proprietary compound LB54640 and will assume sponsorship of two ongoing LGC Phase 2 studies designed to evaluate safety, tolerability, pharmacokinetics and weight loss efficacy of LB54640.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465924001139/0001104659-24-001139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.